Andrzej Adam Ciborek

Dr. Andrzej Adam Ciborek


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2025 in Annals of Agricultural and Environmental Medicine
Verified
Journal Article
Open access
ZCZuzanna Chęcińska-Maciejewska
Zuzanna Chęcińska-Maciejewska
MGMagdalena Gibas-Dorna
Magdalena Gibas-Dorna
BCBartłomiej Czyżniewski
Bartłomiej Czyżniewski
Paweł KołodziejskiPaweł Kołodziejski
Paweł Kołodziejski
EPEwa Pruszynska-Oszmalek
Ewa Pruszynska-Oszmalek
HKHanna Krauss
Hanna Krauss
Introduction and objective: Breastfeeding, particularly in early infancy, plays a crucial role in child health. While its benefits are well documented, few studies have examined how maternal characteristics and sources of breastfeeding knowledge relate to long-term child health outcomes. The...

29 September 2023 in Journal of Pre-Clinical and Clinical Research
Verified
Journal Article
Open access
MWMałgorzata Wojciechowska
Małgorzata Wojciechowska
ZCZuzanna Chęcińska-Maciejewska
Zuzanna Chęcińska-Maciejewska
EPEwa Pruszynska-Oszmalek
Ewa Pruszynska-Oszmalek
ACAndrzej Adam Ciborek
Andrzej Adam Ciborek
MGMagdalena Gibas-Dorna
Magdalena Gibas-Dorna
Paweł KołodziejskiPaweł Kołodziejski
Paweł Kołodziejski
Introduction and objective: Gestational diabetes mellitus (GDM) is a metabolic disease affecting an increasing number of women. The disease not only affects the health of mothers, but may also contribute to metabolic problems in children, both at the stage of foetal life and in the future,...

18 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
DKDariusz Kowalczyk
Dariusz Kowalczyk
JJJolanta Jaworek
Jolanta Jaworek
ACAndrzej Adam Ciborek
Andrzej Adam Ciborek
Paweł KołodziejskiPaweł Kołodziejski
Paweł Kołodziejski
EPEwa Pruszynska-Oszmalek
Ewa Pruszynska-Oszmalek
HKHanna Krauss
Hanna Krauss
Background: The therapeutic management of cutaneous malignancies—cutaneous melanoma, cutaneous squamous-cell carcinoma (cSCC), basal-cell carcinoma (BCC) and Merkel-cell carcinoma (MCC)—has shifted toward multimodal, stage-adapted treatment integrating surgery, radiotherapy, molecularly targeted therapy and immune checkpoint inhibition. Methods: We conducted a structured narrative review with a structured literature search of PubMed/MEDLINE, Scopus and Web of Science (January 2015–6 September 2026), prioritising current clinical practice guidelines, randomised controlled trials and phase II–III studies; landmark older trials were included separately. Synthesis: Surgery with adequate histological margins, including Mohs micrographic surgery where appropriate, remains definitive for localised disease. In resectable macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab with response-driven postoperative management improved event-free survival versus adjuvant nivolumab in NADINA. SWOG S1801 independently demonstrated an event-free-survival advantage for perioperative pembrolizumab over adjuvant-only pembrolizumab in resectable stage III–IV melanoma. In advanced melanoma, dual immune-checkpoint strategies and BRAF/MEK inhibition require patient-specific sequencing; in the European Union, nivolumab plus relatlimab is authorised for first-line advanced melanoma with tumour-cell PD-L1 expression <1%. In high-risk cSCC after surgery and radiotherapy, adjuvant cemiplimab improved disease-free survival. In advanced BCC, Hedgehog-pathway inhibitors remain the principal first systemic option, with anti-PD-1 therapy after HHI failure or intolerance. Clinical implications: Molecular testing should be indication-driven: BRAF V600 is a validated treatment-selecting biomarker, while broader NGS profiling (including NRAS, KIT, NF1, TERT and co-occurring alterations), PD-L1, tumour mutational burden and circulating tumour DNA have context-dependent, supportive or investigational roles. Conclusions: The major unresolved issues are optimal sequencing, response-adapted perioperative treatment, resistance, biomarker validation and treatment of transplant, frail and other under-represented populations.

11 June 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
ZCZuzanna Chęcińska-Maciejewska
Zuzanna Chęcińska-Maciejewska
EPEwa Pruszynska-Oszmalek
Ewa Pruszynska-Oszmalek
Paweł KołodziejskiPaweł Kołodziejski
Paweł Kołodziejski
ACAndrzej Adam Ciborek
Andrzej Adam Ciborek
Hanna Maria KraussHanna Maria Krauss
Hanna Maria Krauss
Elabela (ELA/APELA/Toddler) is an endogenous peptide ligand of the apelin receptor APLNR (also known as APJ) and, together with apelin, forms the apelinergic signalling system. Its role in embryonic development, the cardiovascular system, the kidneys and the endothelium is becoming increasingly well characterised, whilst its function in metabolic regulation remains unresolved. Elabela activates pathways essential for metabolic homeostasis—PI3K/Akt, AMPK-related pathways, redox regulation, inflammatory control and pro-survival cascades—but no study has shown that it directly regulates adipocyte lipid metabolism. This narrative review categorises the evidence at the receptor, organ, immunometabolic and intra-adipocyte levels, and also considers the adipose tissue microenvironment as a distinct level of potential relevance. The available data support a role for Elabela as a candidate mediator of lipid-related metabolic dysfunction—via anti-inflammatory, antioxidant and tissue-protective mechanisms—with macrophage lipid metabolism representing the most informative immunometabolic interface. Human studies remain scarce, heterogeneous and limited by a lack of standardisation in assay methods and the unresolved specificity of isoforms. Elabela should therefore be regarded as a candidate indirect modulator of metabolic homeostasis and a candidate biomarker of cardiometabolic stress or adaptation—not as a confirmed direct regulator of adipocyte lipid metabolism.

7 July 2026 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
ACAndrzej Adam Ciborek
Andrzej Adam Ciborek
ZCZuzanna ChęCińska-Maciejewska
Zuzanna ChęCińska-Maciejewska
ANAgnieszka Nowak
Agnieszka Nowak
HKHanna Krauss
Hanna Krauss
Persistent below-replacement fertility and accelerated population ageing now drive much of the public health agenda in Europe, with measurable consequences for perinatal services and long-term care demand. Aggregate-level data document these trends well; individual-level determinants of fertility intentions in Central European low-fertility settings remain less well characterised. We carried out a cross-sectional online survey in the Greater Poland Voivodeship of Poland between March 2023 and March 2024, recruiting through mixed online channels. The instrument covered demographic, socioeconomic, residential, normative and behavioural domains, including a 10-item Likert scale on perceived barriers to childbearing. The primary outcome was the desired number of children “regardless of existing barriers.” Associations were assessed using Spearman correlation, Kruskal–Wallis and Mann–Whitney tests, and proportional-odds ordinal logistic regression; perceived barriers were summarised by exploratory factor analysis. The sample comprised 1,092 respondents aged 18 to over 40 years, recruited across the rural–urban gradient. The mean desired number of children was 1.84 (SD 1.09); 14.8% wanted no children, while 22.9% wanted three or more. In adjusted ordinal logistic regression, religion influencing family decisions (OR = 2.39; 95% CI 1.75–3.27; p < 0.001), receipt of the 500+ child benefit (OR = 1.58; 95% CI 1.26–1.99; p < 0.001) and age (OR = 1.03 per year; 95% CI 1.02–1.04; p < 0.001) were positively associated with higher reproductive intentions, while urbanisation level was negatively associated (OR = 0.92; 95% CI 0.86–0.99; p = 0.023). Subjective financial situation, educational attainment and perceived influence of the Ukraine war were not significant after adjustment. Factor analysis of the 10 barrier items (KMO = 0.86; Bartlett p < 0.001) identified two dimensions: structural barriers ( α = 0.84; 46.4% of variance), encompassing material situation, housing, partner availability and career ambitions; and psychosocial-normative barriers ( α = 0.80; 13.1% of variance), encompassing fear of parenthood, perceived lack of support and reluctance to change one’s current life. Fertility intentions in this Central European setting are shaped by a heterogeneous mix of structural, normative and life-course factors that cannot be reduced to material conditions alone, supporting a multi-dimensional approach to public health and family policy.

18 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ACAndrzej Adam Ciborek
Andrzej Adam Ciborek
Hanna Maria KraussHanna Maria Krauss
Hanna Maria Krauss
ZCZuzanna Chęcińska-Maciejewska
Zuzanna Chęcińska-Maciejewska
AJAndrzej Jaworek
Andrzej Jaworek
Background/Objectives: Giant keratinocyte carcinomas, comprising basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with a maximum diameter ≥ 5 cm, pose substantial clinical challenges. This structured narrative review distinguishes giant-specific findings from contextual evidence in advanced or high-risk disease. Methods: The synthesis uses a retained bibliography assembled from searches described in earlier drafts as covering PubMed/MEDLINE and PubMed Central from January 2015 to March 2026, supplemented by citation and guideline searching and a focused update reported through 4 September 2026. A record-level search and screening log is unavailable; historical selection counts cannot be independently reconstructed. The review protocol was not registered, and exhaustive coverage or full PRISMA compliance is not claimed. Sources were classified by design and directness, with descriptive consideration of methodological limitations. Results: The retained set contains 51 sources: nine containing direct giant-specific clinical evidence and 42 providing contextual evidence. Direct evidence consists principally of case reports, retrospective or comparative studies and a giant-cSCC literature synthesis. It links giant BCC with prolonged lesion duration, ulceration, deeper invasion and reconstructive burden. Giant-cSCC outcomes vary substantially between reported series. Evidence for Hedgehog-pathway inhibition, PD-1 blockade and most molecular mechanisms derives mainly from conventional or advanced disease. Conclusions: Management requires multidisciplinary assessment integrating size, pathological risk, resectability and patient factors. Giant-specific molecular and therapeutic evidence remains limited, and contextual treatment effects should not be interpreted as effects established specifically in tumours ≥ 5 cm.